Literature DB >> 21233409

Statins inhibit T-acute lymphoblastic leukemia cell adhesion and migration through Rap1b.

Elvira Infante1, Sarah J Heasman, Anne J Ridley.   

Abstract

Statins are known to inhibit signaling of Ras superfamily GTPases and reduce T cell adhesion to ICAM-1. Here, we address the hypothesis that statins affect T cell adhesion and migration by modulating the function of specific GTPases. Statins inhibit the synthesis of mevalonic acid, which is required for farnesyl and geranylgeranyl isoprenoid synthesis. Ras superfamily GTPases are post-translationally isoprenylated to facilitate their anchorage to membranes, where they function to stimulate signal transduction processes. We demonstrate that 1 μM statin inhibits the adhesion, migration, and chemotaxis of the T-ALL cell line CCRF-CEM and TEM of CCRF-CEM and PEER T-ALL cells, but higher statin concentrations are needed to inhibit adhesion of primary T cells. Similar effects are observed following treatment with GGTI-298 or RNA interference-mediated knockdown of Rap1b but not Rap1a, Rac1, Rac2, RhoA, or Cdc42. Statins also alter Rap1 activity and Rap1b localization. Rap1 levels are higher in primary T cells than T-ALL cells, which could explain their reduced sensitivity to statins. These results demonstrate for the first time that the closely related Rap1a and Rap1b isoforms have different functions and suggest that statins or Rap1b depletion could be used to reduce tissue invasion in T-ALL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21233409     DOI: 10.1189/jlb.0810441

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  13 in total

1.  Differential mRNA and long noncoding RNA expression profiles in pediatric B-cell acute lymphoblastic leukemia patients.

Authors:  Jing Xia; Mengjie Wang; Yi Zhu; Chaozhi Bu; Tianyu Li
Journal:  BMC Pediatr       Date:  2022-01-03       Impact factor: 2.125

Review 2.  Roles of Rho GTPases in leucocyte and leukaemia cell transendothelial migration.

Authors:  Elvira Infante; Anne J Ridley
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-09-23       Impact factor: 6.237

3.  Inhibition of geranylgeranyl transferase-I decreases cell viability of HTLV-1-transformed cells.

Authors:  Dustin C Edwards; Katherine M McKinnon; Claudio Fenizia; Kyung-Jin Jung; John N Brady; Cynthia A Pise-Masison
Journal:  Viruses       Date:  2011-10-10       Impact factor: 5.048

4.  Analysis of Rho GTPase expression in T-ALL identifies RhoU as a target for Notch involved in T-ALL cell migration.

Authors:  P J Bhavsar; E Infante; A Khwaja; A J Ridley
Journal:  Oncogene       Date:  2012-02-20       Impact factor: 9.867

5.  Combined treatment with troglitazone and lovastatin inhibited epidermal growth factor-induced migration through the downregulation of cysteine-rich protein 61 in human anaplastic thyroid cancer cells.

Authors:  Li-Han Chin; Sung-Po Hsu; Wen-Bin Zhong; Yu-Chih Liang
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

6.  Roles of Rap1 signaling in tumor cell migration and invasion.

Authors:  Yi-Lei Zhang; Ruo-Chen Wang; Ken Cheng; Brian Z Ring; Li Su
Journal:  Cancer Biol Med       Date:  2017-02       Impact factor: 4.248

7.  miR-28-5p acts as a tumor suppressor in renal cell carcinoma for multiple antitumor effects by targeting RAP1B.

Authors:  Cheng Wang; Caiyun Wu; Qi Yang; Meng Ding; Jinsha Zhong; Chen-Yu Zhang; Jingping Ge; Junjun Wang; Chunni Zhang
Journal:  Oncotarget       Date:  2016-11-08

8.  miR-518b Enhances Human Trophoblast Cell Proliferation Through Targeting Rap1b and Activating Ras-MAPK Signal.

Authors:  Ming Liu; Yongqing Wang; Huifen Lu; Hao Wang; Xiaoming Shi; Xuan Shao; Yu-Xia Li; Yangyu Zhao; Yan-Ling Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-15       Impact factor: 5.555

9.  A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.

Authors:  A L Samuels; A H Beesley; B D Yadav; R A Papa; R Sutton; D Anderson; G M Marshall; C H Cole; U R Kees; R B Lock
Journal:  Blood Cancer J       Date:  2014-08-01       Impact factor: 11.037

10.  The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer.

Authors:  Jessica E Stine; Hui Guo; Xiugui Sheng; Xiaoyun Han; Monica N Schointuch; Timothy P Gilliam; Paola A Gehrig; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Oncotarget       Date:  2016-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.